NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 15, 2023 at 04:11 pm EDT
Share
NEXGEL, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 0.62 million compared to USD 0.396 million a year ago. Net loss was USD 0.814 million compared to USD 1.84 million a year ago.
Basic loss per share from continuing operations was USD 0.15 compared to USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 0.15 compared to USD 0.33 a year ago.
NexGel, Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its gels and its consumer products are manufactured using proprietary and non-proprietary mixing, coating, and crosslinking technologies. It markets under the brand names MedaGel and LumaGel Beauty. The products it sells under its MedaGel brand primarily relate to over the counter (OTC) remedy solutions, such as blister and pain applications; while the products it sells under its LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications. The Company is also engaged in treating the symptoms of Psoriasis through its brand Kenkoderm.
NEXGEL, INC. 
